Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cyberonics Inc announces results from E-36 study of VNS Therapy delivered by The AspireSR Generator

Sunday, 8 Dec 2013 11:00am EST 

Cyberonics Inc:Says that results from the E-36 clinical study of the AspireSR generator were presented at the annual AES Meeting.Says that Paul Boon and clinical research colleagues at 13 other European centers implanted a total of 31 patients with the investigational AspireSR generator, which provides "normal mode" VNS Therapy augmented by seizure response stimulation.Says that after the implant procedure and initial stimulation adjustment period, patients were admitted to an epilepsy monitoring unit for up to five days and monitored to identify seizures and collect heart-rate data.Says that the study met its primary endpoint in that the AspireSR generator, with IntelliSense cardiac-based seizure detection, detected more than 80% of seizures accompanied by ictal tachycardia (heart-rate increase) at a range of programmable settings.Says the potential false detection rates were low. 

Company Quote

0.88 +1.48%
30 Jul 2014